共 362 条
[1]
Antoni S(2017)Bladder cancer incidence and mortality: a global overview and recent trends Eur Urol 71 96-108
[2]
Ferlay J(2017)Nomogram-based Prediction of Overall Survival in Patients with Metastatic Urothelial Carcinoma Receiving First-line Platinum-based Chemotherapy: Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC) European Urology 71 281-289
[3]
Soerjomataram I(2012)Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986 J Clin Oncol 30 191-199
[4]
Znaor A(2005)Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer J Clin Oncol 23 4602-4608
[5]
Jemal A(2013)Oncology meets immunology: the cancer-immunity cycle Immunity 39 1-10
[6]
Bray F(2017)Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial Lancet 389 67-76
[7]
Necchi Andrea(2017)Pembrolizumab as second-line therapy for advanced urothelial carcinoma N Engl J Med 376 1015-1026
[8]
Sonpavde Guru(2016)Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial Lancet 387 1909-1920
[9]
Lo Vullo Salvatore(2017)Atezolizumab in platinum-treated locally advanced or metastatic urothelial carcinoma: post-progression outcomes from the phase II IMvigor210 study Ann Oncol 28 3044-3050
[10]
Giardiello Daniele(2014)MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer Nature 515 558-562